Effect of Antiserotonin Drug on the Development of Lung Fibrosis and Blood System Reactions after Intratracheal Administration of Bleomycin

Скурихин, Е. Г.; Андреева, Т. В.; Khmelevskaya, E. S.; Ермолаева, Л. А.; Першина, О. В.; Krupin, V. A.; Ермакова, Н. Н.; Reztsova, A. M.; Степанова, И. Э.; Goldberg, V. Е.; Дыгай, А. М.

doi:10.1007/s10517-012-1567-1

Cited by 8 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results do not indicate relevant interbreed differences regarding CIPF predisposition and are not in favor of any influence of basal 5-HT concentrations on CIPF development in WHWT. In humans, altered regulation of the serotonin pathway is thought to be associated with the development of pulmonary fibrosis since an increased expression of 5-HT receptors was found in IPF lungs (Fabre and Crestani, 2010;Konigshoff et al, 2010) and anti-serotonin therapy was shown to attenuate induced pulmonary fibrosis in mice (Konigshoff et al, 2010;Skurikhin et al, 2012). In dogs, 5-HT has essentially been studied in the pathogenesis of the DMVD, another fibrotic disease (Oyama and Levy, 2010;Ljungvall et al, 2013;Cremer et al, 2014;Mangklabruks and Surachetpong, 2014).…”

Section: Serum 5-ht Concentrationsmentioning

confidence: 99%

Evaluation of chemokines CXCL8 and CCL2, serotonin, and vascular endothelial growth factor serum concentrations in healthy dogs from seven breeds with variable predisposition for canine idiopathic pulmonary fibrosis

Roels

Krafft

Antoine

et al. 2015

Research in Veterinary Science

View full text Add to dashboard Cite

The West Highland white terrier (WHWT) is particularly prone to canine idiopathic pulmonary fibrosis (CIPF). We hypothesized that higher circulating concentrations of chemokines CXCL8, CCL2, serotonin (5-HT), or vascular endothelial growth factor (VEGF) could serve as predisposing factors for CIPF development in the WHWT breed. Serum samples from 103 healthy dogs of seven different breeds variably predisposed to CIPF were collected. Serum CXCL8 concentrations were higher in healthy WHWT compared with each of the other groups of healthy dogs. Serum CCL2 concentrations were higher in healthy WHWT and Maltese compared with King Charles spaniels and Malinois Belgian shepherds. No relevant inter-breed differences were observed for serum 5-HT concentrations regarding CIPF predisposition. VEGF values from 89.3% of samples tested were below the kit detection limit. In conclusion, high CXCL8 blood concentrations and possibly CCL2 concentrations might be related to the breed predisposition of the WHWT for CIPF and warrants further investigations.

show abstract

Section: Serum 5-ht Concentrationsmentioning

confidence: 99%

Evaluation of chemokines CXCL8 and CCL2, serotonin, and vascular endothelial growth factor serum concentrations in healthy dogs from seven breeds with variable predisposition for canine idiopathic pulmonary fibrosis

Roels

Krafft

Antoine

et al. 2015

Research in Veterinary Science

View full text Add to dashboard Cite

show abstract

“…Increased serotonin can cause vasoconstriction of smooth muscles in the capillary vessels of the lungs thus making a patient hypoxic ( MacLean et al, 2000 ). Over time, such lack of blood flow in the lungs can cause fibrosis that develops in the later, more severe stages of COVID-19 ( Skurikhin et al, 2012 ). Thirdly, serotonin can heighten platelet aggregation ( Almqvist et al, 1984 ), which can contribute to major cardiovascular events.…”

Section: Discussionmentioning

confidence: 99%

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study

et al. 2022

View full text Add to dashboard Cite

Background: The COVID-19 pandemic has impacted millions of lives globally. While COVID-19 did not discriminate against developed or developing nations, it has been a significant challenge for third world countries like Honduras to have widespread availability of advanced therapies. The concept of early treatment was almost unheard of when early outpatient treatments utilizing repurposed drugs in Latin American countries began showing promising results. One such drug is fluvoxamine, which has shown tremendous potential in two major studies. As a direct result, fluvoxamine was added to the standard of care in a major medical center outpatient COVID-19 clinic.Methods: This is a prospective observational study performed at the Hospital Centro Médico Sampedrano (CEMESA) in San Pedro Sula, Cortes, Honduras in the COVID-19 outpatient clinic. All patients were at least 15 years of age who had presented with mild or moderate signs and symptoms of COVID-19, and who also had a documented positive SARS-CoV-2 antigen or Reverse Transcription Polymerase Chain Reaction (RT-PCR) were included in the study. These patients then were all prescribed fluvoxamine. The cohort of patients who decided to take fluvoxamine were compared for primary endpoints of mortality and hospitalization risk to the cohort who did not take fluvoxamine. Patients were then monitored for 30 days with the first follow up at 7 days and the second follow up at 10–14 days of symptom onset. Categorical variables were compared by Pearson Chi-square test. The Relative risk was calculated using regression models. Continuous variables were compared by t-test and Wilcoxon rank-sum tests.Results: Out of total 657 COVID-19 cases, 594 patients took fluvoxamine and 63 did not take fluvoxamine. A total of five patients (0.76 percent) died, with only one death occurring in the fluvoxamine group. Patients who received fluvoxamine had a significantly lower relative risk of mortality (RR 0.06, p 0.011, 95% CI 0.007–0.516). There was a lower relative risk of hospitalization in the patients who in the fluvoxamine group. (−10 vs. 30 hospitalizations, RR 0.49, p = 0.035, 95% CI 0.26–0.95). There was 73 percent reduction in relative risk of requiring oxygen in the fluvoxamine group (RR 0.27, p < 0.001, 95% CI 0.14–0.54 Mean lymphocytes count on the first follow-up visit was significantly higher in the fluvoxamine group (1.72 vs. 1.38, Δ 0.33, p 0.007, CI 0.09–0.58).Conclusion: The results of our study suggest that fluvoxamine lowers the relative risk of death, hospitalization, and oxygen requirement in COVID 19 patients.

show abstract

“…Serious obstacle in particular MSC-therapy is the difficulty to obtain sufficient numbers of cells for transplantation, and the lack of standardized and effective methods to obtain stem cells [39]. Previous studies demonstrated a decrease in damaged lung tissue and collagen deposition in mice with bleo-induced fibrosis, treated with antiserotonin drug cyproheptadine [40,41] and neuroleptic haloperidol [11,42]. The results of our recent studies indicate the involvement of mesenchymal and hematopoietic stem cells in the anti-fibrotic effect of antiserotonin drug and neuroleptic.…”

Section: Discussionmentioning

confidence: 99%

Cholinesterase Enzymes Inhibitory Activities of Methanolic and Aqueous Extracts of Different Parts of

Muniandy¹,

Sadikun²,

Murugaiyah³

2013

TOPROCJ

View full text Add to dashboard Cite

In this study was found that inflammation in interstitial lung tissue of mice C57Bl/6 after intratracheal injection of the bleomycin is accompanied by the increase of the bone marrow and circulating blood cells with the phenotype (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119), Sca-1 + , c-Kit + , CD34 -(hematopoietic stem cells (HSCs)) and hematopoietic progenitor cells (granulocyte-erythroid-macrophage-megakaryocytic (CFU-GEMM) and granulocyte precursors (CFU-G)). These results demonstrate that the intraperitoneal reserpine injection reduces alveolar interstitium and alveolar passages infiltration by inflammatory cells and prevents the connective tissue growth in the lung parenchyma. Supposedly, the reserpine anti-inflammatory effect is caused by the reduced activity of the bone marrow HSCs differentiation in CFU-G, the decrease of circulating HSCs and progenitor hematopoietic cells and the violation of their migration in bleomycin-treated lungs. These data suggest the decrease caused by the reserpine in deposition of collagen fibers in the lung's parenchyma associated with the decrease in the inflow of multipotent mesenchymal stromal cells (MSCs) and fibroblast progenitor bone marrow-derived cells to lungs. Thus, reserpine violates the MSCs differentiation into fibroblast-like cells.

show abstract

Effect of Antiserotonin Drug on the Development of Lung Fibrosis and Blood System Reactions after Intratracheal Administration of Bleomycin

Cited by 8 publications

References 10 publications

Evaluation of chemokines CXCL8 and CCL2, serotonin, and vascular endothelial growth factor serum concentrations in healthy dogs from seven breeds with variable predisposition for canine idiopathic pulmonary fibrosis

Evaluation of chemokines CXCL8 and CCL2, serotonin, and vascular endothelial growth factor serum concentrations in healthy dogs from seven breeds with variable predisposition for canine idiopathic pulmonary fibrosis

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study

Cholinesterase Enzymes Inhibitory Activities of Methanolic and Aqueous Extracts of Different Parts of

Contact Info

Product

Resources

About